{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:10Z","timestamp":1786994410651,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.msard.2025.106352","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:23:24Z","timestamp":1741109004000},"page":"106352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Efficacy of pharmacologic treatments for fatigue in multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-9659","authenticated-orcid":false,"given":"Karlo","family":"Toljan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Aboseif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moein","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106352_bib0001","first-page":"13","article-title":"Evaluating heterogeneous treatment effects in pursuit of personalized multiple sclerosis care","volume":"24","author":"Aboseif","year":"2024","journal-title":"Practical Neurol. (US)"},{"key":"10.1016\/j.msard.2025.106352_bib0002","first-page":"428","article-title":"Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?","volume":"43","author":"Ashtari","year":"2009","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.msard.2025.106352_bib0003","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106352_bib0004","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1038\/s41598-020-61076-1","article-title":"Fatigue profiles in patients with multiple sclerosis are based on severity of Fatigue and not on dimensions of Fatigue","volume":"10","author":"Beckerman","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106352_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103706","article-title":"Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: cross-sectional data from the Swiss Multiple Sclerosis Registry","volume":"60","author":"Bossart","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0006","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/sleep\/33.8.1061","article-title":"Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment","volume":"33","author":"Braley","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.msard.2025.106352_bib0007","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S1474-4422(24)00354-5","article-title":"Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial","volume":"23","author":"Braley","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104993","article-title":"No association between disease modifying treatment and fatigue in multiple sclerosis","volume":"79","author":"Broch","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102586","article-title":"Does oral salbutamol improve fatigue in multiple sclerosis? A pilot placebo-controlled study","volume":"46","author":"De Almeida","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007970","article-title":"Effect of dalfampridine on information processing speed impairment in multiple sclerosis","volume":"93","author":"De Giglio","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106352_bib0011","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/15459683211046257","article-title":"Distinguishing between fatigue and fatigability in multiple sclerosis","volume":"35","author":"Enoka","year":"2021","journal-title":"Neurorehabil. Neural Repair"},{"key":"10.1016\/j.msard.2025.106352_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116844","article-title":"Safety and efficacy of memantine for multiple sclerosis-related fatigue: a pilot randomized, double-blind placebo-controlled trial","volume":"414","author":"Falsafi","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106352_bib0013","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1352458520936226","article-title":"Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis\u2013related fatigue","volume":"27","author":"Fitzgerald","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106352_bib0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","article-title":"The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis","volume":"53","author":"Geisler","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12883-021-02344-z","article-title":"The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey","volume":"21","author":"Gustavsen","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0016","volume":"5","author":"Higgins","year":"2024"},{"key":"10.1016\/j.msard.2025.106352_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2014.00177","article-title":"Management of fatigue in persons with multiple sclerosis","volume":"5","author":"Khan","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0018","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1468-1331.2008.02432.x","article-title":"Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study","volume":"16","author":"Koch","year":"2009","journal-title":"Euro. J. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0019","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1212\/WNL.45.11.1956","article-title":"Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo","volume":"45","author":"Krupp","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106352_bib0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00415-009-0152-7","article-title":"Modafinil effects in multiple sclerosis patients with fatigue","volume":"256","author":"Lange","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7224\/1537-2073.2012-019","article-title":"Psychometric properties of the modified fatigue impact scale","volume":"15","author":"Larson","year":"2013","journal-title":"Int. J. MS Care."},{"key":"10.1016\/j.msard.2025.106352_bib0022","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.clineuro.2013.09.029","article-title":"Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis \u2013 result of a pilot randomized, blind study","volume":"115","author":"Ledinek","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.msard.2025.106352_bib0023","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106352_bib0024","first-page":"3432","article-title":"The comparison of efficacy and safety of N-acetylcysteine and amantadine on fatigue, degree of disability, and quality of life of patients with MS that referred to the MS Association of Khuzestan Province","volume":"20","author":"Majdinasab","year":"2022","journal-title":"Neuro. Quantol."},{"key":"10.1016\/j.msard.2025.106352_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078661","article-title":"Amantadine and\/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical trial","volume":"14","author":"Matias-Guiu","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2025.106352_bib0026","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s13760-024-02508-x","article-title":"Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail","volume":"124","author":"Mavandadi","year":"2024","journal-title":"Acta. Neurol. Belg."},{"key":"10.1016\/j.msard.2025.106352_bib0027","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jama.2014.13128","article-title":"Minimal clinically important difference: defining what really matters to patients","volume":"312","author":"McGlothlin","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2025.106352_bib0028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.msard.2025.106352_bib0029","unstructured":"McMaster University and Evidence Prime, 2024. GRADEpro GDT: gRADEpro Guideline Development Tool."},{"key":"10.1016\/j.msard.2025.106352_bib0030","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/1352458511402410","article-title":"HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis","volume":"17","author":"M\u00f6ller","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106352_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103273","article-title":"Methylphenidate may improve mental fatigue in individuals with multiple sclerosis: a pilot clinical trial","volume":"56","author":"Natsheh","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0032","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2021","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0033","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12883-021-02396-1","article-title":"Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review","volume":"21","author":"Oliva Ramirez","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0034","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106352_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102854","article-title":"Challenges in multiple sclerosis care: results from an international mixed-methods study","volume":"50","author":"P\u00e9loquin","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0036","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1111\/ene.14867","article-title":"Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine","volume":"28","author":"Rocca","year":"2021","journal-title":"Euro. J. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0037","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2019.07.028","article-title":"Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis","volume":"35","author":"Rooney","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0038","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106352_bib0039","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/01.WNL.0000158272.27070.6A","article-title":"Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study","volume":"64","author":"Stankoff","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106352_bib0040","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106352_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102576","article-title":"Tired of not knowing what that fatigue score means? Normative data of the Modified Fatigue Impact Scale (MFIS)","volume":"46","author":"Strober","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.817256","article-title":"Co-occurrence of fatigue and depression in people with multiple sclerosis: a mini-review","volume":"12","author":"Tarasiuk","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0043","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S0317167100026603","article-title":"A randomized controlled trial of Amantadine in fatigue associated with multiple sclerosis","volume":"14","year":"1987","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106352_bib0044","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2003.11.005","article-title":"Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial","volume":"218","author":"Tomassini","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106352_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11940-016-0411-8","article-title":"Fatigue management in multiple sclerosis","volume":"18","author":"Tur","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2025.106352_bib0046","series-title":"Methylphenidate","author":"Verghese","year":"2024"},{"key":"10.1016\/j.msard.2025.106352_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105908","article-title":"Cognitive behavioural therapy for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"91","author":"Vo","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106352_bib0048","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106352_bib0049","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jns.2017.07.042","article-title":"Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"380","author":"Yang","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106352_bib0050","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.36922\/an.2576","article-title":"Fatigue: pharmacological and non-pharmacological management in patients with multiple sclerosis","volume":"3","author":"Yeni","year":"2024","journal-title":"AN."},{"key":"10.1016\/j.msard.2025.106352_bib0051","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2147\/NDT.S429862","article-title":"Overview of the current pathophysiology of fatigue in Multiple sclerosis, its diagnosis and treatment options \u2013 Review article","volume":"19","author":"Zimek","year":"2023","journal-title":"NDT"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:42:40Z","timestamp":1746531760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"alternative-id":["S2211034825000951"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106352","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of pharmacologic treatments for fatigue in multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106352"}}